Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MARS1 | P56192 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359764 | 0.89 | MEN1 (0.52) | MEN1KMT2AMARS1ALDH1A1KDM4E | |
| SCHEMBL31429493 | 0.83 | CA9 (0.53) | KMT2AALDH1A1MAPTSMPD1 | |
| SCHEMBL1738076 | 0.80 | MARS1 (0.64) | RPA1MEN1KMT2AMARS1ALDH1A1 | |
| SCHEMBL27216975 | 0.77 | PTGS1 (0.40) | ALDH1A1KDM4E | |
| SCHEMBL12462471 | 0.76 | P2RY14 (0.36) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1738359 | 0.75 | RPA1 (0.52) | RPA1MEN1KMT2AMARS1ALDH1A1 | |
| SCHEMBL10274612 | 0.75 | PTGER1 (0.43) | — | |
| SCHEMBL596573 | 0.73 | SMN1; SMN2 (0.46) | MARS1ALDH1A1KDM4EL3MBTL1HSD17B10 | |
| SCHEMBL28554732 | 0.73 | MARS1 (0.61) | RPA1MARS1 | |
| SCHEMBL3564370 | 0.73 | SMPD1 (0.59) | RPA1MEN1KMT2AMARS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | RPA1 3876/4885MEN1 3652/4885KMT2A 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.